Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study

[1]  Publisher's Note , 2018, Anaesthesia.

[2]  L. Nazer,et al.  Comparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations , 2017, Journal of clinical pharmacology.

[3]  J. Armitage,et al.  Generic oncology drugs: are they all safe? , 2016, The Lancet. Oncology.

[4]  M. Smid,et al.  Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics , 2015, The Pharmacogenomics Journal.

[5]  P. Neven,et al.  Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors , 2014, BMC Cancer.

[6]  N. Goto,et al.  Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials , 2013, International Journal of Clinical Oncology.

[7]  E. Chu,et al.  Body-surface area-based chemotherapy dosing: appropriate in the 21st century? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Jae Bok Lee,et al.  Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases. , 2011, Journal of cancer research and therapeutics.

[9]  J. Verweij,et al.  Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study , 2011, Clinical Cancer Research.

[10]  Hitoshi Sato,et al.  Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log-binominal regression for febrile neutropenia. , 2009, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[11]  P. Hérait,et al.  Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  G. Hortobagyi,et al.  Docetaxel for treatment of solid tumours: a systematic review of clinical data. , 2005, The Lancet. Oncology.

[13]  J. Verweij,et al.  Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia , 2005, Clinical pharmacology and therapeutics.

[14]  H. Ohmatsu,et al.  Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Wolff,et al.  Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. , 2004, European journal of cancer.

[16]  Roy S Herbst,et al.  Mode of action of docetaxel - a basis for combination with novel anticancer agents. , 2003, Cancer treatment reviews.

[17]  René Bruno,et al.  Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel , 2001, Investigational New Drugs.

[18]  K. Korzekwa,et al.  Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. , 1998, Pharmacogenetics.